Home > Healthcare > Pharmaceuticals > Finished Drug Form > Progesterone Market

Progesterone Market Share

Report ID: GMI8310
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Progesterone Market Share

The progesterone industry is characterized by diverse players competing in the industry. Eli Lily & Company, Glenmark Pharmaceuticals Limited, Novo Nordisk, and Alkem Laboratories Limited, account for significant market share. These prominent players adopt a combination of strategic initiatives such as collaborations & partnerships, global expansion strategies, research and development, product diversification, and regulatory compliance to maintain a competitive edge in the market.

Progesterone Market Companies

The major players operating in the progesterone industry are as mentioned below:

Alkem Laboratories Ltd.
Aquatic Group
Bionpharma Inc.
Cadila Pharmaceuticals
Cipla Inc.
Estrellas Life Sciences Private Limited.
Eli Lily & Company
Glenmark Pharmaceuticals Ltd.
Insud Pharma S.L.U.
Lupin
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of progesterone reached USD 1.3 billion in 2023 and is set to record 12.7% CAGR between 2024 and 2032, attributed to the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis.

The natural segment dominated the market with 58.2% share in 2023, because of its bio-identical nature that closely mimics the progesterone produced by the human body, making it a preferred choice for many patients seeking hormone replacement therapy.

North America market share was 39.2% of the revenue share in 2023, due to the region's advanced healthcare infrastructure, extensive R&D initiatives, and the widespread adoption of progesterone-based therapies for various medical conditions.

Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Cadila Pharmaceuticals, Cipla Inc., Estrellas Life Sciences Private Limited., Eli Lily & Company, Glenmark Pharmaceuticals Ltd., Insud Pharma S.L.U., Lupin, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.